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Summary Serum levels of alpha1-antitrypsin (alAT) were measured by radial immunodiffusion and
phenotypes were determined by electrofocusing in acrylamide gel in 39 patients with hepatocellular carcinoma
(HCC) positive for serum hepatitis B surface antigen (HBsAg), 41 patients with HCC negative for serum
HBsAg, and 160 age- and sex-matched hospital controls. There was no difference between the control series
and either of the two HCC groups with respect to a,AT phenotype pattern; also, there was no evidence of
association between HCC and either the M2 allele or any of the alAT deficiency phenotypes. However, HCC
cases negative for HBsAg had significantly higher serum cx1AT values (mean 665+26mg 100ml-1) than HCC
cases positive for HBsAg (mean 571+23mglOOml-1), who in turn, had significantly higher alAT values than
hospital controls (mean 434+13mg 100ml 1). These results indicate that (i) in Greece, as in other high HCC
incidence countries, genetically determined alAT deficiency is not aetiologically important; (ii) the increase of
serum c,AT is an important correlate of HCC with possible aetiologic significance and diagnostic potential
and (iii) HBsAg-positive HCC and HBsAg-negative HCC are manifest differently as well as being
aetiologically distinct.
Alpha1-antitrypsin (a]AT) is one of nine distinct
plasma proteins which have been characterized as
protease inhibitors (Harpel, 1983); it is a
glycoprotein synthesized in the liver and it is
responsible for about 90 per cent of the tryptic
inhibitory capacity of human serum (Sharp, 1976;
Kew et al., 1978; Morse, 1978; Chio & Oon, 1979).
i1AT is under genetic control, and more than 30
codominant alleles at a single chromosomal locus
have been identified (Chapuis-Cellier, 1975; Cox,
1978; Morse, 1978). Some of these alleles
(particularly the alleles Z, I, S, and perhaps P and
other less common ones) have been associated with
serum cz1AT deficiency of varying degree (Chapuis-
Cellier, 1975; Morse, 1978; Chapuis-Cellier &
Arnaud, 1979) and with the presence in the liver of
periodic acid-Schiff(PAS)-positive, diastase-resistant
globules (Sharp, 1976; Morse, 1978; Palmer et al.,
1980). There appears to be an intriguing link
between a1AT and hepatocellular carcinoma (HCC)
but the evidence is not clear cut (Sharp, 1976; Kew
et al., 1978; Morse, 1978; Kelly et al., 1979). We
have studied the association between e1AT and
HCC in a large group of HCC cases and matched
controls, using adequate laboratory procedures
"blindly" (with respect to disease status), in a
European population with an unusually high
incidence of HCC (Trichopoulos et al., 1982).
Patients and methods
Two hundred and forty patients were studied; they
were Caucasians, of Greek nationality and
residence, hospitalized in one of eight large
hospitals of Athens during a 15-month period in
1976 and 1977. Among them 80 had HCC
(confirmed histologically in 47 cases and by
diagnostic alpha-fetoprotein (aFP) values in the
remaining 33 cases); for each of them two control
patients, matched for age and sex, were selected
from the same hospitals with diagnoses other than
neoplasm or liver disease. Among HCC patients
("cases") 69 (86%) were males and the average age
was 63 years; among comparison patients
("controls") the corresponding figures were 138
males (86%) and 62 years. All patients were
interviewed, and blood samples were taken from
each.
Hepatitis B serologic markers were determined in
all of the sera by radioimmunoassay; samples of 39
cases (49%) and 12 controls (8%) were found to be
positive for hepatitis B surface antigen (HBsAg)
and were considered to have chronic infection. The
two HCC groups (HBsAg positive and HBsAg
negative) were of similar age and sex (mean age, 63
years in both series; proportion of males 85% and
88% respectively). Therefore, age and sex
adjustments were not necessary for comparisons
between controls and either or both of the two
HCC groups (Trichopoulos et al., 1978).
Serum levels and phenotypes of cx1AT were
determined by radial immunodiffusion and
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electrofocusing in acrylamide gel, respectively
(Vesterberg, 1973; Chapuis-Cellier, 1975). All
determinations were performed blindly in the
Department of Clinical Biochemistry of the
Hospital "Edouard Herriot" in Lyon, France.
Results
Table I shows the distributions of HCC cases and
controls by HBsAg status (positive or negative) and
xlAT phenotype pattern. The four distributions are
very similar and the observed differences can easily
be explained by chance. Thus, comparison of all
HCC cases with all controls, with respect to the
four most common alAT phenotypes (and a fifth
group combining all the "other" less common ones)
gives a x2 with 4 degrees of freedom of 2.56,
corresponding to P>0.5. Furthermore, there is no
evidence in the present data that phenotypes
associated with axAT deficiency are over-
represented among HCC cases; on the contrary,
two heterozygotes for the Z allele were included in
the control series whereas none was found among
the cases. Lastly, among the cases 6% were
homozygous and 14% heterozygous for the M2
allele; among controls the corresponding figures
were almost identical (7% and 11%, respectively)
providing no support to the hypothesis that this
allele is associated with a substantial increase of
HCC risk.
Table II shows mean values of serum a;AT (in
mglOOml-') in HCC cases and controls by a1AT
phenotype and, for HCC cases, by HBsAg status.
The mean value of serum a1AT is higher in HCC
cases than in hospital controls (by -40%) and the
difference is highly significant (P< 10 -9). Although
HCC cases of both subgroups have elevated alAT
values the elevation is more marked among
HBsAg-negative cases than among HBsAg-positive
cases; the corresponding mean values are - 50%
and 30% higher than the mean value among
controls and they differ significantly from each
other (P<0.01) as well as from the mean value of
controls (P<10-9 and p< 10-6 respectively). It is
of interest that the pattern HCC (HBsAg-)>
HCC(HBsAg+)>Controls is evident not only in
the total but also within every single alAT
phenotype (with only one marginal exception, in
M1M2). There was no significant (or even similar)
difference in the average level of serum a1AT
between HBsAg positive and negative individuals in
the control group; the mean values were 489 and
430mg 100ml-1 respectively, and the P value for a
t-test of their difference is 0.30. Recent reports
(Trichopoulos et al., 1980; Lam et al., 1982)
indicated that tobacco smoking may cause HBsAg-
negative HCC. Since tobacco smokers in general
have elevated concentrations of serum a1AT, we
have explored whether the very high values ofa,AT
in HCC (and particularly in HBsAg-negative HCC)
could reflect a specific association between a,AT
and tobacco-related HBsAg-negative HCC. There is
some evidence in the present data that this may be
so, but it is far from conclusive. Among patients
with HBsAg-negative HCC, markedly elevated
concentrations of serum x1AT (>600mg 100mlt1)
were found in 21/31 current smokers (68%) but
only in 5/10 non-smokers (50%); however, the
Table I Distribution of HCC cases and controls by HBsAg status and Oe,AT phenotype
HCC cases Controls
AAT
phenotype HBsAg(+) HBsAg(-) Total (%) HBsAg(+) HBsAg(-) Total (%)
MiMi 20 18 38(47) 5 80 85(53)
M1M2 1 5 6(8) 1 10 11(7)
M1M3 13 11 24(30) 5 29 34(21)
M2M2 3 2 5(6) 11 11(7)
M2M3 1 3 4(5) 1 5 6(4)
M3M3 (0) 5 5(3)
M1I 2 2
MIS 1
M1F 1
M1N2 1 1i
M2P (4) 1 1 (5)
M2S 11
M3P j11
M3S 11
M3Z 2 2
Total 39 41 80(100) 12 148 160(100)ALPHA1-ANTITRYPSIN IN LIVER CANCER 569
Table H Concentration of serum alAT in HCC cases (positive and negative for
HBsAg) and in controls, by phenotype. Mean values (and standard errors) in
mglOOml-1
OL1AT HCC cases Controls
phenotype HBsAg(+) HBsAg(-) Total Total
n x n x n x n x
MiMi 20 601 18 675 38 636 85 451
M1M2 1 378 5 619 6 579 11 414
M1M3 13 579 11 645 24 609 34 439
M2M2 3 479 2 888 5 643 11 445
M2M3 1 440 3 661 4 605 6 361
M3M3 5 415
othera 1 466 1 466 3 300
otherb 2 578 2 578 5 312
Total 39 571 41 665 80 619 160 434
(standarderror) (23) (26) (18) (13)
aPhenotypes not reported to be associated with alAT deficiency (M1F, M1N2, M2P,
M P).
Phenotypes reported to be associated with alAT deficiency (M1I, M1S, M2S, M3S,
M3Z).
Table III Distribution of 41 HCC cases negative for HBsAg by
reported smoking habits before the onset of the disease and serum
level ofa1AT (above or below 600mg 00ml-1).
Serum Non (and Ex) Smokers (cigarettes day- 1)
alAT smokers 1-10 11-20 21-30 31+ Totalb
600+ 5 1 11 4 5 26
-599 Sa 2 3 2 3 15
Total 10 3 14 6 8 41
aOne of these patients may have been a regular light smoker
(repeated interview).
b2for trend (1d.f.) =0.5;P>0.25.
difference is neither statistically significant nor
dose-dependent (Table III).
We have also investigated whether, among HCC
patients, there is a positive correlation between the
serum concentrations of aFP (after log-
transformation) and a1AT. There is no such
evidence in the present data; among HBsAg-
positive HCC patients the correlation coefficient is
+0.04, whereas among HBsAg-negative HCC
patients the corresponding value is +0.05.
Discussion
The association between alAT and HCC has been
studied from several points of view. Individuals
who are homozygous for the Z allele (and perhaps
other alleles associated with a1AT deficiency) have
an increased risk for HCC, and many of them have
the characteristic globular bodies in their livers.
However, it is not clear whether individuals who
B
are heterozygous for these alleles are at increased
risk for HCC; many studies have noted modest
associations but several others have not, even
though heterozygotes have consistently the same
characteristic globules in their livers (studies
reviewed by Sharp, 1976; Kew et al., 1978; Morse,
1978; Kelly et al., 1979; Sizaret et al., 1981; Spech
& Liehr, 1982). Kew et al. (1978) have summarized
the evidence by stating that a1AT deficiency could
be an occassional cause of the tumour in most parts
of the world where HCC occurs sporadically, but it
is not a numerically important cause in Africa and
the Far East where HCC is common. Our findings
support this conclusion and permit its
generalization to other populations where HCC is
common, besides those of Africa and Asia. On the
other hand, we did not confirm the associations of
HCC with the F or the M2 alleles, which were
reported by Theodoropoulos et al. (1976) and
Sizaret et al. (1981), respectively. Since the present
study is larger than the other two we are inclined to570 L. SPAROS et al.
believe that the earlier findings were, perhaps,
fortuitous.
Elevated values of serum a,AT in HCC cases
have been noted by Kew et al., (1978), Chio & Oon
(1979), and Matsuzaki et al. (1981). Our findings
confirm the results of the earlier investigations and
indicate that the elevation is sufficiently marked to
be aetiologically intriguing and diagnostically
useful. Furthermore, we have found that serum
a1AT values are, on the average, higher in HBsAg-
negative cases of HCC than in HBsAg-positive
cases of this tumour-an observation not reported
previously. Although the difference is not
sufficiently large to be of clinical importance it
suggests that the aetiologic heterogeneity of HCC is
reflected not only in the epidemiologic parameters
but also in the laboratory findings of the aetiologic
subgroups.
The molecular, biochemical and histological
aspects of the association between aeAT and HCC
have been reviewed elsewhere (Sharp, 1976; Morse,
1978; Palmer et al., 1980; Spech & Liehr, 1982).
However, the differential increase of acAT in
HBsAg-positive and HBsAg-negative HCC, if real,
calls for explanation. Several possibilities exist.
Tobacco smoking has been found to increase the
serum levels of alAT by -20% (Lellouch et al.,
1979) and this proportional excess may also
concern the tobacco related HCC cases. It should
be noted, also, that cirrhosis is associated with
reduced levels of serum alAT (Chio & Oon, 1979;
Matsuzaki et al., 1981), and cirrhosis (in Greece, at
least) is more frequently associated with HBsAg-
positive than with HBsAg-negative HCC
(Trichopoulos et al., 1982).
Palmer et al. (1980), using ultrastructural,
histochemical and immunocytochemical methods
have demonstrated the occasional parallel
emergence of aFP and acAT as tumour tissue
markers in malignant hepatoma (HCC). It is,
therefore, surprising that a significant positive
association was not evident between the serum
values of aFP and a1AT in the present study or in
the earlier study of Chio & Oon (1979). Although
chance is a likely explanation for the absence of a
significant association, it is also possible that the
epigenetic emergence of ajAT as tumour tissue
marker is not frequently accompanied by an
increase in the serum levels of ciAT (Palmer et al.,
1980).
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